专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011016780A Cell growth inhibitor and an anti-cancer agent 有权
标题翻译：细胞增殖抑制剂和抗原剂
公开(公告)号：JP2011016780A
公开(公告)日：2011-01-27
申请号：JP2009164181
申请日：2009-07-10
申请人： Ishihara Sangyo Kaisha Ltd , 石原産業株式会社
发明人： KIMURA HIROHIKO , TSUKAMOTO MASAMITSU , YOTSUYA SHUICHI , SHIKAMA HIROSHI
IPC分类号： C07D333/56 , A61K31/381 , A61P35/00 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a cell proliferation inhibitor containing a new compound or a pharmacologically acceptable salt thereof or both thereof as active ingredients, and to provide an anticancer agent.SOLUTION: There is provided the compound represented by formula (I) [wherein, A is hydrogen, alkyl, hydroxy, -COOR(Ris hydrogen or alkyl which may be substituted with cycloalkyl), -CONRR(Rand Rare each independently hydrogen or alkyl) or a halogen; q is an integer of 1-4; Rand Rare each independently hydrogen or alkyl; Ris alkyl or a halogen; Ris specific benzothiophene] or the pharmacologically acceptable salt thereof.
摘要翻译：要解决的问题：提供含有新化合物或其药理学上可接受的盐或其两者作为活性成分的细胞增殖抑制剂，并提供抗癌剂。溶液：提供由式（I）表示的化合物[其中，A是氢，烷基，羟基，-COOR（Ris氢或可以被环烷基取代的烷基），-CONRR（Rand Rare各自独立地是氢或烷基）或卤素; q为1-4的整数; 兰德稀有各自独立的氢或烷基; Ris烷基或卤素; Ris特异性苯并噻吩]或其药理学上可接受的盐。

2. 发明专利

JP2011006384A Anti-shock agent containing diaminotrifluoromethylpyridine derivative 有权
标题翻译：含有二氨基二氟甲基吡啶衍生物的抗震剂
公开(公告)号：JP2011006384A
公开(公告)日：2011-01-13
申请号：JP2010110765
申请日：2010-05-13
申请人： Ishihara Sangyo Kaisha Ltd , 石原産業株式会社
发明人： YOTSUYA SHUICHI , SHIKAMA HIROSHI
IPC分类号： A61K31/44 , A61P9/00 , C07D213/76
CPC分类号： C07D213/76 , A61K31/44 , C07D409/12
摘要： PROBLEM TO BE SOLVED: To provide a medicine for treating septic shock by suppressing infiltration by inflammatory cells since it is known that septic shock leads to systemic inflammatory syndrome and multiple organ failure (MOF) in late stages, eventually leading to death, both the diseases eventually lead to death by way of MOF, and the infiltration by inflammatory cells largely involves the development of MOF.SOLUTION: There is provided a therapeutic or prophylactic agent for shock, which contains a diaminotrifluoromethylpyridine derivative represented by formula (I) [wherein, X represents cycloalkylcarbonyl, alkenylcarbonyl, thiophenecarbonyl, or benzoyl which may be substituted by a halogen atom; and Y represents alkylsulfonyl] or a salt thereof as an active ingredient.
摘要翻译：要解决的问题：提供一种通过抑制炎性细胞浸润来治疗败血性休克的药物，因为已知脓毒性休克导致全身性炎症综合征和多器官功能衰竭（MOF）在晚期，最终导致死亡最终通过MOF导致死亡，并且炎性细胞的浸润主要涉及MOF的发展。解决方案：提供了用于休克的治疗或预防剂，其包含由式（I）表示的二氨基三氟甲基吡啶衍生物[其中，X 表示可被卤素原子取代的环烷基羰基，烯基羰基，噻吩羰基或苯甲酰基; Y表示烷基磺酰基]或其盐作为有效成分。

3. 发明专利

JP2004166695A CONTROL OF RAPL-Rap1 INTERACTION 审中-公开
标题翻译： RAPD-Rap1相互作用的控制
公开(公告)号：JP2004166695A
公开(公告)日：2004-06-17
申请号：JP2003370258
申请日：2003-10-30
申请人： Ishihara Sangyo Kaisha Ltd , 石原産業株式会社
发明人： KINASHI TATSUO , SHIKAMA HIROSHI
IPC分类号： A01K67/027 , A61K31/44 , A61K31/443 , A61K38/00 , A61K45/00 , A61K48/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K14/47 , C07K16/18 , C12N15/09 , C12P21/08 , G01N33/15 , G01N33/50
摘要： PROBLEM TO BE SOLVED: To understand pathologic conditions of immune diseases, such as inflammation, allergies, autoimmune diseases, cancerous immune diseases, and transplantation immunological rejection, and to develop a method for treating the diseases, by clarifying a mechanism of integrin adhesiveness control by Pap1, because it is thought that functional failure of the Rap1 as an integrin adhesiveness controlling molecule closely relates to the pathologic conditions of the immune diseases. SOLUTION: An inhibitor in binding of p30 to the Rap1, etc., is developed by utilizing a discovery that the p30 binds to the Rap1 and controls its function, while the p30 is identified as a molecule relating to the integrin adhesiveness control by the Pap1, so that a remedy for the inflammation, the allergies, the autoimmune diseases, the cancerous immune diseases, the transplantation immunological rejection, etc., is developed and further control mechanisms of the diseases are clarified. COPYRIGHT: (C)2004,JPO
摘要翻译：要解决的问题：了解炎症，过敏，自身免疫疾病，癌性免疫疾病和移植免疫排斥等免疫疾病的病理状况，并开发一种治疗疾病的方法，通过澄清整合素的机制由于认为Rap1作为整合素粘附控制分子的功能衰竭与免疫疾病的病理状况密切相关，因此Pap1的粘附控制。解决方案：通过利用p30结合Rap1并控制其功能的发现开发了p30与Rap1等结合的抑制剂，而p30被鉴定为与整联蛋白粘附性控制有关的分子通过Pap1，开发了炎症，过敏，自身免疫性疾病，癌性免疫疾病，移植免疫排斥反应等的补救措施，并阐明了疾病的进一步控制机制。版权所有（C）2004，JPO

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式